A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer

A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer

Background: The AR-V7 splice variant is a cause of castration-resistant prostate cancer (CRPC). However, testing for the presence of AR-V7 by real-time polymerase chain reaction (RT-PCR) shows AR-V7 positivity in healthy individuals. We hypothesized that the positivity reflects contamination by hema...

Full description

Bibliographic Details
Main Authors: Takehiko Nakasato, Chiho Kusaka, Mika Ota, Yuki Hasebe, Kumiko Ueda, Tsutomu Unoki, Kazuhiko Oshinomi, Jun Morita, Yoshiko Maeda, Takeshi Shichijo, Michio Naoe, Yoshio Ogawa
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Diagnostics
Subjects:
ar-v7
androgen receptors
docetaxel
cabazitaxel
abiraterone
enzalutamide
Online Access:https://www.mdpi.com/2075-4418/10/3/151

Internet

https://www.mdpi.com/2075-4418/10/3/151

Similar Items